Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/26/24
End: 06/30/28
Due: 06/30/29
Phase: N/A
Priority: Normal
Start: 11/29/22
End: 02/28/27
Due: 02/28/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| AB-2100, an Integrated Circuit T (ICT) Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) | NCT06245915 | Arsenal Biosciences, Inc. | user2@example.com | None | 2024-02-26 | 2028-06-30 | 2029-06-30 | - | - | 2025-07-14 |
| AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer | NCT05617755 | Arsenal Biosciences, Inc. | user2@example.com | None | 2022-11-29 | 2027-02-28 | 2028-02-28 | - | - | 2025-07-14 |